- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Spectrum enters into license deal for Phase III PTCL drug
TopoTarget has entered into a licensing deal with Spectrum Pharmaceuticals for Belinostat, TopoTarget's Phase III lymphoma drug.
The deal gives Spectrum an additional lymphoma-related product to go along with Zevalin.
Belinostat (PXD 101) was granted orphan drug status by the FDA in September 2009 for the treatment of peripheral t-cell lymphoma (PTCL). It is believed to work by blocking enzymes required for cell division and by stunting the development of blood vessels in tumors.